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Background
Hepatitis B virus (HBV) is one of ideal models to study on the viral mutation and evolu-
tion, because the rapid and imprecise replication produce a high rate of non-synony-
mous mutations, which are able to provide the virus much more chances to adapt the 
circumstances, on the contrary, functional constraint of the viral gene weeds out those 
lethal mutations, so the HBV genomes present not only diversity, but also relative con-
servation (Zhang et al. 2010).
With the accumulation of HBV genome sequences, there are eight natural genotypes 
(A–H) identified around the world (Miyakawa and Mizokami 2003; Schaefer 2007), 
among which the genotype A is mainly prevalent in Europe, the genotype B and C are 
prevalent in China and nearby regions and genotype D is mainly from Africa and mid-
dle east, etc. (Zeng et  al. 2005; Kao et  al. 2002; Wang et  al. 2007; Schaefer 2007). In 
these years, wide application of the nucleotide analogue results in the HBV drug resist-
ance. The typical YMDD motif variation (rtM204I/V) could be found in the reverse 
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transcriptase (RNA-dependent DNA polymerase, RT) from all the genotypes, after the 
patients with HBV infection took a long-term treatment of the lamivudine (Malmstrom 
et al. 2007; Zhang et al. 2003; Moskovitz et al. 2005). These provoke us great interests to 
study the evolutionary selection of HBV under this specific condition.
Recently, more and more research works illustrate that YMDD variation is not a single 
mutation of rtM204I/V in the RT, but companied by compensatory mutation, such as 
rtL180M, etc. (Thai et al. 2012; Zoulim and Locarnini 2009). On the other hand, HBV 
genotype is not only predictive of clinical outcomes but has also been associated with 
response to anti-virus treatment (Lin and Kao 2011; Akuta and Kumada 2005). Mean-
while, the YMDD variant types might be different among the genotypes (Li et al. 2006). 
Nevertheless, many aspects about molecular variation of different YMDD mutations and 
HBV genotypes are still obscure, further studies are needed to deeply reveal these issues. 
Fortunately, there has been plenty of information about HBV drug resistance available 
in the public sequence database now, which brings great convenience to address the 
question.
Given these, here we, using bioinformatics techniques, attempt to make a comprehen-
sive investigation of the molecular variation of the RT region among genotype A–D, in 




The amino acid sequences of HBV polymerase with the genotype information were 
obtained from a knowledge database for hepatitis B virus, HBVdb (Hayer et al. 2013). 
There were totally 3871 sequences from genotype A–D, out of which, 439 YMDD muta-
tions were harvested from different genotypes. Moreover, the polymerase sequences 
with sub-genotype information were got from NBCI protein database for the reference 
during the phylogeny tree drawing.
Screen of the variant sites
After a multiple alignment by Muscle module of Mega software (6.0 version) (Tamura 
et al. 2011), the RT regions were extracted from each polymerase protein sequences by 
our in-house Perl program, at the same time, they were divided into different groups 
according to the genotype, variant type and wild type.
Because single mutations commonly occur in the biological sequence, no matter 
among variant or wild type groups there might exist different amino acids in one site. 
Thus, it is needed to distinguish the drug-induced compensatory mutations from ran-
dom mutations, here we adopted the naïve Bayes classification algorithm to estimate the 
amino acids in each site, which mostly exist in the variant samples rather than wild sam-
ples, according to the following formula: 
 where the maximum posterior (tmap) represents the mostly type (variant or wild type) 
that the amino acid of each site belongs to. The probability of mutative rate is denoted 
tmap = arg max
t∈T
P(a|t)P(t)
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by P(t), referring to the index from an epidemiological investigation (Hann et al. 2008). 
The probabilities of every amino acids from different types P(a) were independently cal-
culated by above collected data. Given this, if the amino acid with more than 35 % com-
position rate had a tmap belonging to the variant type, the variant site was screened out. 
In addition, the genotyping sites could be also identified between different genotypes by 
this approach.
Identification of co‑variant patterns
To completely display the co-variant characters, we constructed a complete induction 
algorithm to series-connect the changed amino acids into a combined pattern, accord-
ing to above variant sites. Given this, the patterns of each sequence were obtained by our 
in-house Perl program. The percentage of each pattern was calculated at the same time.
Meanwhile, a co-evolution analysis was carried out in order to figure out the co-vari-
ant features of the above variant sites by using CAPS 1.0 (Fares and McNally 2006). Due 
to the limitation of this algorithm and the novel requirement for the hardware, we just 
select some representative sequences from every group to run CAPS at a 0.001 alpha 
value in our Ubuntu Server with the memory of 16G. In addition,  the  Fastcov 1.03, a 
newly-developed bioinformatics tool  (Shen and Li 2016), was used for covariant analy-
sis of the full data. The results were used to be the additional evidence along with the 
former co-variance pattern analysis.
Chi square test
A Chi Square Test was used to measure a goodness of fit between an observed and 
expected distribution of quantity of YMDD variants among different genotypes, the 
functions of CHITEST and CHIINV (probability, freedom degree) were used to calcu-
late the Chi Square test statistic in Excel sheet. The difference of observed and expected 
distribution was determined by the P value less than 0.05.
Phylogenetic analysis
Phylogenetic analysis was performed with maximum likelihood approach for revealing 
the evolutionary relationships of the co-variant mutations to the different sub-geno-
types, and an phylogeny tree was constructed and drawn as a radiation graphic by Mega 
6.0 (Tamura et al. 2011).
Results
Different occurrences of YMDD variants among genotypes
Although several types of YMDD variants were previously reported, the most frequent 
types were the YIDD and YVDD (Pan et al. 2007; Ono-Nita et al. 1999). Table 1 showed 
Table 1 Distribution of different YMDD variants with different genotypes
Wild YIDD YVDD I/V ratio
Genotype A 596 10 132 0.1
Genotype B 963 35 13 2.7
Genotype C 1118 83 66 1.3
Genotype D 755 74 26 2.8
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that the occurrence rates of two types of mutations were significant different among 
A–D genotypes. By Chi square test, the occurrence rates of the YIDD type were gener-
ally higher than those of YVDD in genotype B, C and D, but on the contrary, the rate of 
YVDD type was significantly higher than that of YIDD in genotype A (I/V ratio = 0.1, 
P = 0.001). Based on the coden degeneracy principle, any mutation occurred at the third 
nucleotide of the triplet coden would change the M into I, and only if the mutation of 
A->G at the first one of the triplet coden could change the M into V, else into L or R, but 
the latter two are quite rare in fact. It seemed the YIDD mutation should occur naturally 
higher than the YVDD. Interestingly, the reverse feature of genotype A exactly presented 
a fact that the mutation was subject to the restriction of function or structure much 
more than the coden degeneracy principle.
Variant characters of different YMDD mutations
To investigate the variant character of the RT region, the comparative analysis was per-
formed between the wild and the mutation groups from different genotypes, by the naïve 
Bayes classification algorithm. The variant sites where the amino acid composition were 
changed more than 35 % with a higher probability of mutation were harvested (Fig. 1).
Generally, the covariant sites and rates were not same in different mutational types 
and genotypes. The YIDD mutations (left column of Fig. 1) came along with much more 
variant sites than the YVDD mutations (right column of Fig.  1) in all the genotypes. 
Among these sites, the rtL180 M came along with rtM204I/V as previous reports, but 
here we noticed it was not along with rtM204I in genotype B and majority of genotype 
C. Meanwhile, more co-variances were detected at other sites.
Based on the large data of wild types, the single amino acid polymorphism could be 
found at many sites. While the covariance occurred at those sites, the amino acids com-
position ratio was generally inverted, such as those at site of 53 and 219, etc. It reflected 
the natural polymorphism provided the possibility for the selection. Interestingly, their 
converted ratios were always lower than that of rtM204I/V itself. So the non-synchro-
nous conversion supported the fact of the compensatory variance after YMDD mutation.
Moreover, we noticed that some variances occurred at the historical genotyping sites 
(labeled by asterisk in Table  2), among which, new amino acid could appear, such as 
rtR13L in genotype B, but many of them trended to transform into other genotyping 
amino acid, such as rtL91I in genotype D, etc. Anyway, it displayed an interesting fact 
that the genotyping sites could be influenced once again while the much more variances 
took place under the new condition and pressure, and the single amino acid polymor-
phism reflected that these sites were less conserved, but the flexibility might be useful 
for the structural balance.
Co‑variant patterns of YMDD variants
To clarify the covariance followed by the YMDD mutation, we investigated the multiple-
sites combined co-variant status. Using the complete induction method to series-con-
nect the variant sites, the co-variant patterns were checked out from every RT sequence.
Table 3 showed the co-variant patterns were commonly existed in all kinds of muta-
tional types and genotypes. It demonstrated the previously reported rtL180 M was not 
the unique compensatory variance. Especially, the co-variant patterns in the YIDD type 
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Fig. 1 Amino acids composition at every variant site of the mutations in comparison to those of the wild 
types from different genotypes. Note: The minus Y axis is just used to display the wild type, which still means 
the positive value. The * represents the genotyping site
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were much longer than those in the YVDD type. Meanwhile, the co-variant patterns 
were different in every genotype.
Because the co-variant patterns expressed multiple status in every column (Table 3), 
it presented a dynamic transforming process. As the CAPS analysis, inter-molecular 
co-evolving sites were classified into different subgroups, for instance, the subgroup 
consisted by 53 and 204 covariant sites, and that by 207 and 219 covariant sites, etc., 
but the CAPS could not synchronously detect all of these pattern sites. Taken together, 
it reflected that the co-variance went through several steps during the evolutionary 
process, and the multiple-sites combined co-variance trended to an ideal state after 
rtM204I/V mutation. Moreover, the Fastcov obtained quite similar covariant patterns to 
those in Table 3 based on the intergroup data, but not from the whole data. That meant 
the drug-induced single mutation promoted different compensatory mutations related 
to the subgroups.
The evolution of HBV followed with YMDD mutation
For the multiple-sites co-variances caused by drug-induced YMDD mutation, it was 
necessary to deeply figure out their evolutionary relationship. As we known, HBV geno-
types differ by more than 8 % using the sequence of its complete genome or 4 % using 
the sequence of small surface protein (Schaefer 2005). Here using naïve Bayes classifica-
tion model, we checked out that at least 5 % of RT region were different among genotype 
A–D, but the sub-genotypes differed by at least 4 amino acids. Therefore, the mutational 
Table 2 Changing features of every variant at different sites
Site Wild YIDD YVDD Wild YIDD YVDD Wild YIDD YVDD Wild YIDD YVDD
7 * D T T A T
13 * H R L N H
16 * I T I I T
53 * I T N S N D
80 L L L i L I
91 * I L I L I
135 S S Y S S
159 S T S S S
180 L M M L M L m M L M M
204 M I V M I V M I V M I V
207 V I V I V V
219 S A S S S
222 * T A T T T T
229 L L F L L F
259 * T T S T S
271 * H M L Q E
316 Q Q Q Q h
337 N N T N N
Genotype A Genotype B Genotype C Genotype D
 
The genotyping sites (the genotype‑characteristic amino acid located) are labeled by asterisk, where the changed amino 
acids are rounded by a black frame and those transforming to other genotype are in gray background
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RT sequences with 4 or more amino acids combined co-variant patterns were targeted 
for evolutionary analysis.
Based on the maximum likelihood algorithm, the phylogeny tree was drawn for the 
co-variant RT sequences against the NCBI recorded sub-genotypes (Fig. 2). It showed 
that the co-variant sequences still located in their original genotype, but all of them were 
clustered into independent branches (called Cov branches in Fig. 2) against the known 
sub-genotypes. The result suggested that these co-variances resulted in the formation of 
new sub-groups. It reflected that the flexibility of RT sequences provided the chance of 
adaptive selection, and drug-induced mutation could push the evolution of RT region.
Discussion
In this study, we have made a comprehensive investigation on the YMDD variants from 
genotype A, B, C and D. By the naïve Bayes classification algorithm and the complete 
induction method based on the comparative sequence analysis, this study presents 
more detailed subsequent mutations followed with the lamivudine-induced rtM204I/V 
mutation. In contrast to the previous reports based on the longitudinal analysis (Thai 
et al. 2012; Zoulim and Locarnini 2009), this study conducts a cross-sectional analysis 
of integrity data by using bioinformatics techniques. From the hierarchy view, we clar-
ify that historical mutations, drug-induced mutation and compensatory variances, and 
demonstrate the co-variant patterns associated with the YMDD variant types and HBV 
Fig. 2 Phylogeny tree of the co-variant strains against the known sub-genotypes. Note: The co-variant amino 
acid at site of 204 was in lowercase
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genotypes. This study displayed an inter-conditioned relationship of amino acid vari-
ances during multiple evolutionary processes.
For the lamivudine-induced mutation itself, the data shows that the genotype A tends 
to acquire rM204V mutation type, but the number of covariant sites of rM204V is much 
less that of rM204I. Because the historical genotyping mutations had already appeared 
before the drug-induced mutation, we could distinguish the subsequent amino acid 
changes as the compensatory variance. Although the lamivudine-induced rtM204I/V 
mutation might occur in any genotype, the compensatory mutations are not consistent 
in different genotypes. For instance, the previous studies reported a high incidence rate 
of rtL180M followed by YMDD variance, here we deeply figure out that the rtL180M is 
generally followed by rtM204V, but it is less followed by rtM204I in genotype C, and rare 
rtL180M by rtM204I in genotype B. Moreover, a set of subsequent amino acid changes 
took place after drug-induced mutation, and formed different co-variant patterns in dif-
ferent YMDD variant types and HBV genotypes. It reflects that compensatory variances 
of amino acids are subject to the former morphology of viral protein. That means that 
the RT is not only diversity, but also restricted. On the other hand, because some co-var-
iant sites could influence the genotyping sites, this interesting adaptive selection under a 
special pressure suggests the flexibility of these historical sites take part in the structural 
balance as well.
Drug-induced mutation seems begin with one site (Song et al. 2012), and be followed 
with more or less compensatory mutations. Because the 3D structural modeling has 
shown that rt180 in the rt173–189 helix is close enough to interact with rtM204 of the 
YMDD loop (Allen et al. 1998), the rtL180M is ever regarded as the rational explanation 
to the compensatory mutation. But here we provide new evidence that rtL180M hardly 
exists in rtM204I of genotype B and C, it means the rtL180M is not a unique key site to 
remain 3D structural balance, and other covariance also could contribute to the struc-
tural and functional stability of the RT.
In the previous study, we have illustrated the different evolutionary selection of multi-
ple genes from the longest overlapping region of HBV genome, and testified functional 
restriction based on the amino acid sequence finally determined the selection, no matter 
which codon site the mutation occurs in the nucleotide sequence. Different from the 
pressure in overlapping region, this study demonstrates the adaptive selection under 
drug pressure. But both of the results consistently support that the functional restriction 
and structural stability essentially determine the HBV selection.
The diversity of co-variant patterns reflects a powerful fitness of viral protein, and it 
puts up a serious challenge to the anti-HBV therapies. So this study supports that the 
drug combination, i.e. lamivudine and adefovir combination therapy, might be useful to 
increase the difficulty of evolutionary selection. In spite of this, the multiple-drug resist-
ance might still occur (Inoue et al. 2011; Chotiyaputta and Lok 2009; Mello et al. 2012; 
Yatsuji et al. 2007). Fortunately, some drugs, i.e. tenofovir or entecavir, have rarely been 
reported to be resistant (Agarwal et al. 2015; Colonno et al. 2006). It suggests that some 
crucial sites in amino acid sequence should be unchangeable where any mutation might 
be lethal for the virus.
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Conclusions
From the hierarchy view, we clarified that historical mutations, drug-induced mutation 
and compensatory variances. Although occurrence of the YMDD mutation itself was not 
related to the HBV genotypes, the subsequence co-variant patterns are different, which 
are related to the YMDD variant types and HBV genotypes. This study not only extends 
our understanding of molecular evolution and powerful fitness of viral protein, but also 
a subtle relationship of structural polymorphs and the function, which should be consid-
ered for anti-virus drug design, development and treatment.
Authors’ contributions
YC and YL designed the study, contributed significantly in data analysis and manuscript preparation. YL programmed the 
software and wrote the manuscript. NW, XW took part in the data statistical analysis. KZ carried out data management. 
All authors read and approved the final manuscript.
Author details
1 Medical Research Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. 2 Depart-
ment of Infectious Diseases, No. 324 Hospital of PLA, Chongqing 400020, China. 3 Department of Microbiology, Third 
Military Medical University, Chongqing 400038, China. 
Acknowledgements
This work was supported by Natural Science Foundation Project of CQ, No: CSTC 2014jcyja10076, and the Fund of viral 
hepatitis prevention and treatment of China, No. 47, 2014.
Competing interests
The authors declare that they have no competing interests.
Received: 7 October 2015   Accepted: 5 August 2016
References
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutch-
ison JG, Gane EJ, Foster GR (2015) Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir 
alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62(3):533–540. doi:10.1016/j.jhep.2014.10.035
Akuta N, Kumada H (2005) Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob 
Chemother 55(2):139–142. doi:10.1093/jac/dkh533
Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD (1998) Identification and 
characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. 
Hepatology 27(6):1670–1677. doi:10.1002/hep.510270628
Chotiyaputta W, Lok AS (2009) Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 6(8):453–462. doi:10.1038/
nrgastro.2009.107
Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, 
Plym M, Klesczewski K, Tenney DJ (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. 
Hepatology 44(6):1656–1665. doi:10.1002/hep.21422
Fares MA, McNally D (2006) CAPS: coevolution analysis using protein sequences. Bioinformatics 22(22):2821–2822. 
doi:10.1093/bioinformatics/btl493
Hann HW, Gregory VL, Dixon JS, Barker KF (2008) A review of the one-year incidence of resistance to lamivudine in the 
treatment of chronic hepatitis B: Lamivudine resistance. Hep Intl 2(4):440–456. doi:10.1007/s12072-008-9105-y
Hayer J, Jadeau F, Deleage G, Kay A, Zoulim F, Combet C (2013) HBVdb: a knowledge database for Hepatitis B Virus. 
Nucleic Acids Res 41 (Database issue):D566–D570. doi:10.1093/nar/gks1022
Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K, Obara N, Iwasaki 
T, Shimosegawa T (2011) Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant 
hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepatitis 
18(3):206–215. doi:10.1111/j.1365-2893.2010.01301.x
Kao JH, Liu CJ, Chen DS (2002) Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 36(2):303–304
Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T (2006) YMDD mutations and genotypes of hepatitis B virus in 
northern China. Jpn J Infect Dis 59(1):42–45
Lin CL, Kao JH (2011) The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 
26(Suppl 1):123–130. doi:10.1111/j.1440-1746.2010.06541.x
Malmstrom S, Hannoun C, Lindh M (2007) Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan 
PCR. J Virol Methods 143(2):147–152. doi:10.1016/j.jviromet.2007.03.001
Mello FC, Lago BV, Lewis-Ximenez LL, Fernandes CA, Gomes SA (2012) Detection of mixed populations of wild-type and 
YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol 12(1):96. 
doi:10.1186/1471-2180-12-96
Miyakawa Y, Mizokami M (2003) Classifying hepatitis B virus genotypes. Intervirology 46(6):329–338. 
doi:10.1159/000074988
Page 11 of 11Cai et al. SpringerPlus  (2016) 5:1340 
Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ (2005) Response to long-term lamivudine treatment (up to 
5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepatitis 12(4):398–
404. doi:10.1111/j.1365-2893.2005.00613.x
Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M (1999) YMDD motif in hepatitis B virus DNA poly-
merase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. 
Hepatology 29(3):939–945. doi:10.1002/hep.510290340
Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF (2007) Differences of YMDD mutational patterns, precore/core promoter 
mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepatitis 14(11):767–
774. doi:10.1111/j.1365-2893.2007.00869.x
Schaefer S (2005) Hepatitis B virus: significance of genotypes. J Viral Hepatitis 12(2):111–124. 
doi:10.1111/j.1365-2893.2005.00584.x
Schaefer S (2007) Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13(1):14–21
Shen W, Li Y (2016) A novel algorithm for detecting multiple covariance and clustering of biological sequences. Sci Rep 
6:30425. doi:10.1038/srep30425
Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H (2012) Diagnostic and therapeutic progress of multi-drug resistance with 
anti-HBV nucleos(t)ide analogues. World J Gastroenterol 18(48):7149–7157. doi:10.3748/wjg.v18.i48.7149
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis 
using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28(10):2731–
2739. doi:10.1093/molbev/msr121
Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo CG, Lok A, Khudyakov Y (2012) Con-
vergence and coevolution of hepatitis B virus drug resistance. Nature Commun 3:789. doi:10.1038/ncomms1794
Wang Z, Huang Y, Wen S, Zhou B, Hou J (2007) Hepatitis B virus genotypes and subgenotypes in China. Hepatol Res Off J 
Jpn Soc Hepatol 37(s1):S36–S41. doi:10.1111/j.1872-034X.2007.00102.x
Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, 
Suzuki F, Kumada H, Chayama K (2007) Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med 
Virol 79(12):1811–1817. doi:10.1002/jmv.20981
Zeng G, Wang Z, Wen S, Jiang J, Wang L, Cheng J, Tan D, Xiao F, Ma S, Li W, Luo K, Naoumov NV, Hou J (2005) Geographic 
distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepatitis 12(6):609–
617. doi:10.1111/j.1365-2893.2005.00657.x
Zhang X, Liu C, Gong Q, Zhang S, Zhang D, Lu Z, Wang Y (2003) Evolution of wild type and mutants of the YMDD motif of 
hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol 18(12):1353–1357
Zhang D, Chen J, Deng L, Mao Q, Zheng J, Wu J, Zeng C, Li Y (2010) Evolutionary selection associated with the multi-
function of overlapping genes in the hepatitis B virus. Infect Genetics Evol J Mol Epidemiol Evol Genet Infect Dis 
10(1):84–88. doi:10.1016/j.meegid.2009.10.006
Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137 (5):1593–1608 
(e1591–e1592). doi:10.1053/j.gastro.2009.08.063
